Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Passarelli A, Bartoletti M, Farolfi A, Iacovino ML, Perrone F, Schettino C, Arenare L, Montico M, Baldassarre G, Califano D, Pisano C, Andretta V, Artioli G, Bergamini A, Bianco R, Bologna A, Lorusso D, Fagotti A, Gentile M, Napolitano S, Poletto E, Savarese A, Scandurra G, Valabrega G, Zamagni C, Lin YG, Maatouk L, Pignata S.

Open source

DOI: 10.1016/j.ijgc.2026.104957
Published: 2026-08-09
Container: Int J Gynecol Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2026.104957,
  title = {Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.},
  author = {Passarelli A and  Bartoletti M and  Farolfi A and  Iacovino ML and  Perrone F and  Schettino C and  Arenare L and  Montico M and  Baldassarre G and  Califano D and  Pisano C and  Andretta V and  Artioli G and  Bergamini A and  Bianco R and  Bologna A and  Lorusso D and  Fagotti A and  Gentile M and  Napolitano S and  Poletto E and  Savarese A and  Scandurra G and  Valabrega G and  Zamagni C and  Lin YG and  Maatouk L and  Pignata S.},
  year = {2026},
  journal = {Int J Gynecol Cancer},
  doi = {10.1016/j.ijgc.2026.104957},
  url = {https://doi.org/10.1016/j.ijgc.2026.104957}
}

RIS

TY  - JOUR
TI  - Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.
AU  - Passarelli A
AU  -  Bartoletti M
AU  -  Farolfi A
AU  -  Iacovino ML
AU  -  Perrone F
AU  -  Schettino C
AU  -  Arenare L
AU  -  Montico M
AU  -  Baldassarre G
AU  -  Califano D
AU  -  Pisano C
AU  -  Andretta V
AU  -  Artioli G
AU  -  Bergamini A
AU  -  Bianco R
AU  -  Bologna A
AU  -  Lorusso D
AU  -  Fagotti A
AU  -  Gentile M
AU  -  Napolitano S
AU  -  Poletto E
AU  -  Savarese A
AU  -  Scandurra G
AU  -  Valabrega G
AU  -  Zamagni C
AU  -  Lin YG
AU  -  Maatouk L
AU  -  Pignata S.
PY  - 2026
JO  - Int J Gynecol Cancer
DO  - 10.1016/j.ijgc.2026.104957
UR  - https://doi.org/10.1016/j.ijgc.2026.104957
ER  -

APA

A, P., M, B., A, F., ML, I., F, P., C, S., L, A., M, M., G, B., D, C., C, P., V, A., G, A., A, B., R, B., A, B., D, L., A, F., M, G., S, N., E, P., A, S., G, S., G, V., C, Z., YG, L., L, M., & S., P. (2026). Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.. Int J Gynecol Cancer. https://doi.org/10.1016/j.ijgc.2026.104957

Source records

europe-pmc · retrieved 2026-09-25T23:50:56.695Z